Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs

European Neuropsychopharmacology

Volumn 24, Issue 7, 2014, Pages 1046-1055

  Samara, Myrto T ^a   Cao, Haoyin ^a,b   Helfer, Bartosz ^a,b   Davis, John M ^c,d   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Antipsychotics; Chlorpromazine; First generation; Meta analysis; Randomized; Response

Indexed keywords

BENZQUINAMIDE; BUTAPERAZINE; CHLORPROMAZINE; CLOMACRAN; CLOPENTHIXOL; CLOTIAPINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LENPERONE; LEVOMEPROMAZINE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; OXYPERTINE; PECAZINE; PENFLURIDOL; PERPHENAZINE; PIMOZIDE; PIPERACETAZINE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RESERPINE; SULPIRIDE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOTEPINE;

ARTICLE; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; COMPARATIVE STUDY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84902277349     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.03.012     Document Type: Article

References (83)

1. Abraham J., Davis C. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Soc. Sci. Med. 2005, 61:881-892.
2. Adams, C.E., Awad, G., Rathbone, J., Thornley, B., 2007. Chlorpromazine versus placebo for schizophrenia. The Cochrane database of systematic reviews, CD000284.
3. Ahmed, U., Jones, H., Adams, C.E., 2010. Chlorpromazine for psychosis induced aggression or agitation. The Cochrane database of systematic reviews, CD007445.
4. Amin M.M., Ban T.A., Lehmann T.A. A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients. Psychopharmacol. Bull. 1977, 13:20-21.
5. AstraZeneca, 2000. A multicentre, double-blind, randomised trial to compare the effects of SEROQUEL and chlorpromazine in patients with treatment resistant schizophrenia (5077IL/0054 [TRESS]).
6. AstraZeneca, 2005. A multicentre, double-blind, randomised comparison of quetiapine (SEROQUEL) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia (5077IL/0031).
7. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K.F., Simel D., Stroup D.F. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J. Am. Med. Assoc. 1996, 276:637-639.
8. Bian Z.X., Li Y.P., Moher D., Dagenais S., Liu L., Wu T.X., Miao J.X., Kwan A.K., Song L. Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology. J. Chin. Integr. Med. 2006, 4:120-129.
9. Bland J.M., Altman D.G. Multiple significance tests: the Bonferroni method. Br. Med. J. 1995, 310:170.
10. Bohnke J.R., Lutz W. [Including or excluding data: intention-to-treat and completer analyses]. Daten ein- oder ausschlieSSen: intention-to-treat- und Completer-Analysen. Psychother Psychosom. Med. Psychol. 2012, 62:429.
11. Borenstein M., Hedges L., Higgins J., Rothstein H. Comprehensive Meta-Analysis 2005, Biostat, Englewood, NJ. 2nd ed.
12. Bratfos O., Haug J.O. Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study. Acta Psychiatrica Scandinavica 1979, 60:1-9.
13. Buchanan R.W., Carpenter W.T. Schizophrenia. Comprehensive Textbook of Psychiatry 2000, Lippincott Williams & Wilkins, Philadelphia, (Chapter 12). 7th ed. B.J. Sadock, V.A. Sadock (Eds.).
14. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W., Schizophrenia Patient Outcomes Research, T. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
15. Centre T.N.C. Review Manager (RevMan) 2012, The Cochrane Collaboration, Copenhagen. 5.2 ed.
16. Christison G.W., Kirch D.G., Wyatt R.J. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr. Bull. 1991, 17:217-245.
17. Conley R.R., Tamminga C.A., Bartko J.J., Richardson C., Peszke M., Lingle J., Hegerty J., Love R., Gounaris C., Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry 1998, 155:914-920.
18. Davies H.T., Crombie I.K., Tavakoli M. When can odds ratios mislead?. Br. Med. J. 1998, 316:989-991.
19. Davis J.M., Barter J.T., Kane J.M. Antipsychotic drugs. Comprehensive Textbook of Psychiatry 1989, 1591-1626. Williams and Wilkins, Baltimore. 5th ed. H.J. Kaplan, B.J. Saddock (Eds.).
20. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003, 60:553-564.
21. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin. Tr. 1986, 7:177-188.
22. Dold M., Leucht S. Is haloperidol more effective than other first-generation antipsychotics in schizophrenia? A meta-analysis of randomized controlled trials. Schizophr. Res. 2012, 136(Suppl. 1):S263-S264.
23. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
24. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997, 315:629-634.
25. Egger M., Zellweger-Zahner T., Schneider M., Junker C., Lengeler C., Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997, 350:326-329.
26. Fleming B.G., Spencer A.M., Whitelaw E.M. A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis. J. Ment. Sci. 1959, 105:349-358.
27. Furukawa T.A., Akechi T., Wagenpfeil S., Leucht S. Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophr. Res. 2011, 126:212-219.
28. Geller V., Gorzaltsan I., Shleifer T., Belmaker R.H., Bersudsky Y. Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophr. Res. 2005, 80:343-347.
29. Gregoire G., Derderian F., Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?. J. Clin. Epidemiol. 1995, 48:159-163.
30. Guaiana, G., Barbui, C., Hotopf, M., 2007. Amitriptyline for depression. The Cochrane database of systematic reviews, CD004186.
31. Guy, W., 1976. Clinical Global Impressions, ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338), Revised DHEW ed. Rockville, Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, pp. 218-222.
32. Hamilton M., Smith A.L.G., Lapidus H.R., Cadogan E.P. A controlled trial of thiopropazate dihydrochloride (dartalan), chlorpromazine and occupational therapy in chronic schizophrenics. J. Ment. Sci. 1960, 106:40-55.
33. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions 2011, Wiley and Sons, Chichester, UK, (Version 5.1.0 [updated March 2011]).
34. Hong C.J., Chen J.Y., Chiu H.J., Sim C.B. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int. Clin. Psychopharmacol. 1997, 12:123-130.
35. Honigfeld G., Patin J., Singer J. Clozapine antipsychotic activity in treatment-resistant schizophrenics. Adv. Therapy 1984, 1:77-97.
36. Howanitz E., Pardo M., Smelson D.A., Engelhart C., Eisenstein N., Stern R.G., Losonczy M.F. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J.Clin. Psychiatry 1999, 60:41-44.
37. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
38. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
39. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
40. Kane J.M., Khanna S., Rajadhyaksha S., Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 2006, 21:21-28.
41. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
42. Kishimoto T., Agarwal V., Kishi T., Leucht S., Kane J.M., Correll C.U. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol. Psychiatry 2013, 18:53-66.
43. Klein D., Davis J. Diagnosis and Drug Treatment of Psychiatric Disorders 1969, Williams and Wilkins, Baltimore MD.
44. Lal S., Thavundayil J.X., Nair N.P.V., Annable L., Kin N.M.K.N., Gabriel A., Schwartz G. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. J. Psychiatry Neurosci. 2006, 31:271-279.
45. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J., American Psychiatric, A., Steering Committee on Practice, G. Practice guideline for the treatment of patients with schizophrenia, second ed. Am. J. Psychiatry 2004, 161:1-56.
46. Leon A.C. Implications of clinical trial design on sample size requirements. Schizophr. Bull. 2008, 34:664-669.
47. Leucht, C., Kitzmantel, M., Chua, L., Kane, J., Leucht, S., 2008. Haloperidol versus chlorpromazine for schizophrenia. The Cochrane Database of Systematic Reviews, CD004278.
48. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013.
49. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
50. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining [U+05F3]response[U+05F3] in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2007, 32:1903-1910.
51. Leucht S., Engel R.R. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacol.: Official Publ. Am. Coll. Neuropsychopharmacol. 2006, 31:406-412.
52. Leucht S., Engel R.R., Bauml J., Davis J.M. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophr. Bull. 2007, 33:183-191.
53. Leucht S., Engel R.R., Davis J.M., Kissling W., Meyer Zur Capellen K., Schmauss M., Messer T. Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 2012, 22:501-505.
54. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry: the J. Ment. Sci. 2005, 187:366-371.
55. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361:1581-1589.
56. Levine S.Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 2008, 98:318-322.
57. Lewis S.W., Barnes T.R., Davies L., Murray R.M., Dunn G., Hayhurst K.P., Markwick A., Lloyd H., Jones P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32:715-723.
58. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2003, 28:995-1003.
59. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
60. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., Clinical Antipsychotic Trials of Intervention Effectiveness, I. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
61. Marshall M., Lockwood A., Bradley C., Adams C., Joy C., Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br. J. Psychiatry: J. Ment. Sci. 2000, 176:249-252.
62. McCreadie R.G., MacDonald I.M. High dosage haloperidol in chronic schizophrenia. Br. J. Psychiatry 1977, 131:310-316.
63. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
64. Mercer G., Finlayson A., Johnstone E.C., Murray C., Owens D.G. A study of enhanced management in patients with treatment-resistant schizophrenia. J. Psychopharmacol. 1997, 11:349-356.
65. Moher D., Fortin P., Jadad A.R., Juni P., Klassen T., Le Lorier J., Liberati A., Linde K., Penna A. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996, 347:363-366.
66. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 2009, 62:1006-1012.
67. Moher D., Pham B., Klassen T.P., Schulz K.F., Berlin J.A., Jadad A.R., Liberati A. What contributions do languages other than English make on the results of meta-analyses?. J. Clin. Epidemiol. 2000, 53:964-972.
68. Neal C.D., Collis M.P., Imlah N.W. A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia. Curr. Ther. Res. Clin. Exp. 1969, 11:367-378.
69. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
70. Peuskens J., Link C.G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. 1997, 96:265-273.
71. Rajotte P., Bordeleau J.M., Tetreault L. Comparative study of butaperazine and prochlorperazine in chronic schizophrenia. Can. Psychiatr. Assoc. J. 1965, 10:25-34.
72. Simon W., Wirt R., Wirt A., Halloran A., Hinckley R., Lund J., Hopkins G.W. A controlled study of the short-term differential treatment of schizophrenia. Am. J. Psychiatry 1958, 114:1077-1086.
73. Stahl S.M. 11. Antipsychotic Agents, Essential Psychopharmacology: Neuroscientific Basis and Practical Applications 2000, Press Syndicate of the University of Cambridge Cambridge, United Kingdom. second ed.
74. StataCorp Stata Statistical Software: Release 12 2011, StataCorp LP, College Station, TX.
75. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 2006, 163:611-622.
76. Team R.C. R: A Language and Environment for Statistical Computing 2012, R Foundation for Statistical Computing, Vienna, Austria.
77. Thornley B., Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br. Med. J. 1998, 317:1181-1184.
78. Toru M., Shimazono Y., Miyasaka M., Kokubo T., Mori Y., Nasu T. A double-blind comparison of sulpiride with chlorpromazine in chronic schizophrenia. J. Clin. Pharmacol. New Drugs 1972, 12:221-229.
79. Trikalinos T.A., Churchill R., Ferri M., Leucht S., Tuunainen A., Wahlbeck K., Ioannidis J.P.A., Project, E.-P. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J. Clin. Epidemiol. 2004, 57:1124-1130.
80. WHO, World Health Organization Model List of Essential Medicines, 17th list (March 2011).
81. Wilson I.C., McKay J., Sandifer M.G. A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. J. Ment. Sci. 1961, 107:90-99.
82. Wu T.X., Li Y.P., Liu G.J. Investigation of Authenticity of [U+05F3]Claimed[U+05F3] Randomized Controlled Trials (RCTs) and Quality Assessment of RCT Reports Published in China 2006, XIV Cochrane Colloquium Dublin, Ireland.
83. Zhang J.P., Gallego J.A., Robinson D.G., Malhotra A.K., Kane J.M., Correll C.U. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. 2012, 1-14.